Changshan Biochemical Pharmaceutical Set To Expand Heparin API Output
This article was originally published in PharmAsia News
Executive Summary
The heparin API workshop of Changshan Biochemical Pharmaceutical has passed an on-site inspection and audit, and is now in the publicized GMP period from June 18 to July 1, 2014, after which it is expected to gradually increase manufacturing output to 3.85 trillion units.